

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1653hxp

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * Welcome to STN International * * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS 4 OCT 28 KOREAPAT now available on STN
NEWS 5 NOV 30 PHAR reloaded with additional data
NEWS 6 DEC 01 LISA now available on STN
NEWS 7 DEC 09 12 databases to be removed from STN on December 31, 2004
NEWS 8 DEC 15 MEDLINE update schedule for December 2004
NEWS 9 DEC 17 ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS 10 DEC 17 COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS 12 DEC 17 CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS 14 DEC 30 EPFULL: New patent full text database to be available on STN
NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED
NEWS 16 JAN 03 No connect-hour charges in EPFULL during January and February 2005

NEWS EXPRESS OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 19:13:32 ON 05 JAN 2005

FULL ESTIMATED COST

ENTRY
0.21

SESSION
0.21

FILE 'MEDLINE' ENTERED AT 19:14:05 ON 05 JAN 2005

FILE 'BIOSIS' ENTERED AT 19:14:05 ON 05 JAN 2005
Copyright (c) 2005 The Thomson Corporation.

FILE 'BIOTECHDS' ENTERED AT 19:14:05 ON 05 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 19:14:05 ON 05 JAN 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 19:14:05 ON 05 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'FSTA' ENTERED AT 19:14:05 ON 05 JAN 2005
COPYRIGHT (C) 2005 International Food Information Service

FILE 'DGENE' ENTERED AT 19:14:05 ON 05 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'JAPIO' ENTERED AT 19:14:05 ON 05 JAN 2005
COPYRIGHT (C) 2005 Japanese Patent Office (JPO) - JAPIO

FILE 'USPATFULL' ENTERED AT 19:14:05 ON 05 JAN 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JICST-EPLUS' ENTERED AT 19:14:05 ON 05 JAN 2005
COPYRIGHT (C) 2005 Japan Science and Technology Agency (JST)

FILE 'WPIX' ENTERED AT 19:14:05 ON 05 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'SCISEARCH' ENTERED AT 19:14:05 ON 05 JAN 2005
Copyright (c) 2005 The Thomson Corporation.

=> s (p53) and (ATM or atacia-telangiectasia mutated?)
L1 2748 (P53) AND (ATM OR ATACIA-TELANGIECTASIA MUTATED?)

=> s ATM or Ataxia-telangiectasia mutated?
L2 170895 ATM OR ATAXIA-TELANGIECTASIA MUTATED?

=> s (p53)
L3 205530 (P53)

=> s l3 and l2
L4 2824 L3 AND L2

=> s l4 an l1
MISSING OPERATOR L4 AN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l4 and l1
L5 2748 L4 AND L1

=> s l5 and binding
L6 842 L5 AND BINDING

=> s (P53) and (binding) and (ATM)
L7 842 (P53) AND (BINDING) AND (ATM)

=> s (p53) and (binding) and (ATR)
L8 218 (P53) AND (BINDING) AND (ATR)

=> s 18 and 17
L9 177 L8 AND L7

=> s phosphorylation and 19
L10 122 PHOSPHORYLATION AND L9

=> e Meyn /au
E1 3 MEYMERIT J C/AU
E2 2 MEYMOUNA M/AU
E3 1 --> MEYN/AU
E4 7 MEYN A/AU
E5 2 MEYN A W/AU
E6 1 MEYN ADIER J/AU
E7 1 MEYN ASHLEIGH W/AU
E8 3 MEYN B/AU
E9 51 MEYN C/AU
E10 2 MEYN C K/AU
E11 1 MEYN CATHERINE K/AU
E12 18 MEYN CORNELIS/AU

=> s e5
L11 2 "MEYN A W"/AU

=> d 111 ti abs ibib tot

L11 ANSWER 1 OF 2 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

TI The Extraction and Infrared Identification of Gamma-Hydroxybutyric Acid
(GHB) from Aqueous Solutions.

AB The chemical analysis of gamma-hydroxybutyric acid (GHB) in most forensic laboratories is complicated by the highly polar nature of the GHB molecule, which makes it unsuitable for direct analysis by gas chromatography (GC). Consequently, a popular analytical approach is to convert GHB into the corresponding lactone or a derivative compound that is then identified by mass spectrometry employed in conjunction with GC (GC/MS). An alternative approach is presented here where GHB may be isolated as a free acid specie from complex aqueous solutions employing a liquid-liquid extraction technique. This approach can yield a relatively pure residue of GHB that presents an infrared transmission spectrum that is sufficiently distinct for identification purposes. Infrared spectroscopy (IR) is a very popular technique that is available to most crime laboratories. The liquid-liquid extraction behavior of GHB is examined in detail and the uniqueness of the infrared spectrum is discussed.

ACCESSION NUMBER: 2004023417 EMBASE

TITLE: The Extraction and Infrared Identification of
Gamma-Hydroxybutyric Acid (GHB) from Aqueous Solutions.

AUTHOR: Chappell J.S.; Meyn A.W.; Ngim K.K.

CORPORATE SOURCE: Dr. J.S. Chappell, Drug Enforcement Administration, Western
Laboratory, 390 Main Street, San Francisco, CA 94105,
United States

SOURCE: Journal of Forensic Sciences, (2004) 49/1 (52-59).

Refs: 25

ISSN: 0022-1198 CODEN: JFSCAS

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 029 Clinical Biochemistry
049 Forensic Science Abstracts

LANGUAGE: English

SUMMARY LANGUAGE: English

L11 ANSWER 2 OF 2 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on
STN

TI The extraction and infrared identification of Gamma-hydroxybutyric acid
(GHB) from aqueous solutions

AB The chemical analysis of gamma-hydroxybutyric acid (GHB) in most forensic laboratories is complicated by the highly polar nature of the GHB molecule, which makes it unsuitable for direct analysis by gas chromatography (GC). Consequently, a popular analytical approach is to convert GHB into the corresponding lactone or a derivative compound that is then identified by mass spectrometry employed in conjunction with GC (GC/MS). An alternative approach is presented here where GHB may be isolated as a free acid specie from complex aqueous solutions employing a liquid-liquid extraction technique. This approach can yield a relatively pure residue of GHB that presents an infrared transmission spectrum that is sufficiently distinct for identification purposes. Infrared spectroscopy (IR) is a very popular technique that is available to most crime laboratories. The liquid-liquid extraction behavior of GHB is examined in detail and the uniqueness of the infrared spectrum is discussed.

ACCESSION NUMBER: 2004:80679 SCISEARCH

THE GENUINE ARTICLE: 762DV

TITLE: The extraction and infrared identification of
Gamma-hydroxybutyric acid (GHB) from aqueous solutions

AUTHOR: Chappell J S (Reprint); Meyn A W; Ngim K K

CORPORATE SOURCE: Drug Enforcement Adm, Western Lab, 390 Main St, Room 700,
San Francisco, CA 94105 USA (Reprint); Drug Enforcement
Adm, Western Lab, San Francisco, CA 94105 USA

COUNTRY OF AUTHOR: USA

SOURCE: JOURNAL OF FORENSIC SCIENCES, (JAN 2004) Vol. 49, No. 1,
pp. 52-59.

Publisher: AMER SOC TESTING MATERIALS, 100 BARR HARBOR DR,
W CONSHOHOCKEN, PA 19428-2959 USA.

ISSN: 0022-1198.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 24

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

=> d his

(FILE 'HOME' ENTERED AT 19:13:32 ON 05 JAN 2005)

FILE 'MEDLINE, BIOSIS, BIOTECHDS, EMBASE, WPIDS, FSTA, DGENE, JAPIO,
USPATFULL, JICST-EPLUS, WPIX, SCISEARCH' ENTERED AT 19:14:05 ON 05 JAN
2005

L1 2748 S (P53) AND (ATM OR ATACIA-TELANGIECTASIA MUTATED?)

L2 170895 S ATM OR ATAXIA-TELANGIECTASIA MUTATED?

L3 205530 S (P53)

L4 2824 S L3 AND L2

L5 2748 S L4 AND L1

L6 842 S L5 AND BINDING

L7 842 S (P53) AND (BINDING) AND (ATM)

L8 218 S (P53) AND (BINDING) AND (ATR)

L9 177 S L8 AND L7

L10 122 S PHOSPHORYLATION AND L9

E MEYN /AU

L11 2 S E5

=> s 18 and phosphorylation

L12 156 L8 AND PHOSPHORYLATION

=> s 112 and screening method

7 FILES SEARCHED...

L13 19 L12 AND SCREENING METHOD

=> s l10 and screening method

8 FILES SEARCHED...

L14 12 L10 AND SCREENING METHOD

=> d l13 ti abs ibib tot

L13 ANSWER 1 OF 19 USPATFULL on STN

TI Stress-responsive activator of p300 (strap) protein

AB The invention provides a protein which is a stress-responsive activator of the p300 protein, and nucleic acid sequences encoding the protein. The protein performs a key role in facilitating stress-responsive protein-protein interactions within the p300 co-activator complex. The STRAP protein facilitates the interaction of other proteins in the p300 complex, and is thus a target for assays for modulators of the complex.

ACCESSION NUMBER: 2004:328237 USPATFULL

TITLE: Stress-responsive activator of p300 (strap) protein

INVENTOR(S): La Thangue, Nicholas Barnie, Strathclyde, UNITED KINGDOM

Demonacos, Constantinos, Strathclyde, UNITED KINGDOM
Krstic-Demonacos, Marija, Strathclyde, UNITED KINGDOM

NUMBER KIND DATE

| | | | |
|---------------------|----------------|----|---------------|
| PATENT INFORMATION: | US 2004260062 | A1 | 20041223 |
| APPLICATION INFO.: | US 2004-471573 | A1 | 20040816 (10) |
| | WO 2002-GB1349 | | 20020319 |

NUMBER DATE

| | | |
|-----------------------|--------------|----------|
| PRIORITY INFORMATION: | GB 2001-6782 | 20010319 |
|-----------------------|--------------|----------|

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: NIXON & VANDERHYE, PC, 1100 N GLEBE ROAD, 8TH FLOOR,
ARLINGTON, VA, 22201-4714

NUMBER OF CLAIMS: 24

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 17 Drawing Page(s)

LINE COUNT: 2276

L13 ANSWER 2 OF 19 USPATFULL on STN

TI p53-dependent apoptosis-inducing protein and method of screening for apoptosis regulator

AB p53-dependent Damage-Inducible Nuclear Protein 1 (p53DINP1 protein) is a p53-induced nuclear protein that induces p53-dependent apoptosis by regulating p53 function through Ser 46 phosphorylation. A DNA encoding p53DINP1 can be applied as anticancer agents for destroying neoplasms such as tumors, and as therapeutic or preventive agents for diseases associated with p53-mediated apoptosis abnormalities. It is also possible to apply the above protein and DNA in methods of screening for candidate compounds for regulating p53-mediated apoptosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:320942 USPATFULL

TITLE: p53-dependent apoptosis-inducing protein and method of screening for apoptosis regulator

INVENTOR(S): Nakamura, Yusuke, Kanagawa, JAPAN
Arakawa, Hirofumi, Tokyo, JAPAN

NUMBER KIND DATE

PATENT INFORMATION: US 2004253595 A1 20041216
APPLICATION INFO.: US 2004-484157 A1 20040726 (10)
WO 2002-JP7305 20020718

| | NUMBER | DATE |
|--|--|----------|
| PRIORITY INFORMATION: | JP 2001-220349 | 20010719 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | Kevin Bastian, Townsend and Townsend and Crew, Two
Embarcadero Center, Eighth Floor, San Francisco, CA,
94111-3834 | |
| NUMBER OF CLAIMS: | 13 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 10 Drawing Page(s) | |
| LINE COUNT: | 1897 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | |

L13 ANSWER 3 OF 19 USPATFULL on STN

TI Modulators of telomere stability
AB The present invention embodies methods of modulating telomere repeat-binding factor-2 (TRF2) or cell cycle checkpoint kinase 2 (Chk2) to enhance the survival of a cell. More particularly, the modulators can be used to treat cardiovascular disease by improving the growth and survival of cardiomyocytes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:307785 USPATFULL
TITLE: Modulators of telomere stability
INVENTOR(S): Schneider, Michael D., Houston, TX, UNITED STATES
Oh, Hidemasa, Houston, TX, UNITED STATES

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2004242461 | A1 | 20041202 |
| APPLICATION INFO.: | US 2004-820583 | A1 | 20040408 (10) |

| | NUMBER | DATE |
|--|--|---------------|
| PRIORITY INFORMATION: | US 2003-461095P | 20030408 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | FULBRIGHT & JAWORSKI, LLP, 1301 MCKINNEY, SUITE 5100,
HOUSTON, TX, 77010-3095 | |
| NUMBER OF CLAIMS: | 30 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 34 Drawing Page(s) | |
| LINE COUNT: | 4939 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | |

L13 ANSWER 4 OF 19 USPATFULL on STN

TI Novel SMG-1
AB A novel polypeptide and a novel polynucleotide encoding the same are disclosed.

The polypeptide is SMG-1, a protein included in the phosphatidyl inositol kinase related kinase family, and is useful in constructing a screening system for agents of treating and/or preventing a disease caused by a premature translation termination codon generated by a nonsense mutation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:178425 USPATFULL
TITLE: Novel SMG-1

INVENTOR(S) : Ohno, Shigeo, Tokyo, JAPAN
PATENT ASSIGNEE(S) : Japan Science and Technology Agency, Saitama, JAPAN
(non-U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---|------|---------------|
| PATENT INFORMATION: | US 2004137592 | A1 | 20040715 |
| APPLICATION INFO.: | US 2003-720460 | A1 | 20031124 (10) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. WO 2001-JP10234, filed on 22 Nov 2001, UNKNOWN | | |

| | NUMBER | DATE |
|--|--|----------|
| PRIORITY INFORMATION: | JP 2001-156088 | 20010524 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | HESLIN ROTHENBERG FARLEY & MESITI PC, 5 COLUMBIA CIRCLE, ALBANY, NY, 12203 | |
| NUMBER OF CLAIMS: | 19 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 14 Drawing Page(s) | |
| LINE COUNT: | 3702 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | |

L13 ANSWER 5 OF 19 USPATFULL on STN
TI Modulation of checkpoint kinase 1 expression
AB Compounds, compositions and methods are provided for modulating the expression of checkpoint kinase 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding checkpoint kinase 1. Methods of using these compounds for modulation of checkpoint kinase 1 expression and for diagnosis and treatment of disease associated with expression of checkpoint kinase 1 are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:127462 USPATFULL
TITLE: Modulation of checkpoint kinase 1 expression
INVENTOR(S) : Gaarde, William, Carlsbad, CA, UNITED STATES
Freier, Susan M., San Diego, CA, UNITED STATES
Dobie, Kenneth W., Del Mar, CA, UNITED STATES
Watt, Andrew T., Vista, CA, UNITED STATES
PATENT ASSIGNEE(S) : Isis Pharmaceuticals Inc. (U.S. corporation)

| | NUMBER | KIND | DATE |
|--|--|------|---------------|
| PATENT INFORMATION: | US 2004097446 | A1 | 20040520 |
| APPLICATION INFO.: | US 2002-298994 | A1 | 20021116 (10) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | APPLICATION | | |
| LEGAL REPRESENTATIVE: | WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE - 46TH FLOOR, PHILADELPHIA, PA, 19103 | | |
| NUMBER OF CLAIMS: | 24 | | |
| EXEMPLARY CLAIM: | 1 | | |
| LINE COUNT: | 3681 | | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | | |

L13 ANSWER 6 OF 19 USPATFULL on STN
TI Novel proteases
AB The present invention relates to protease polypeptides, nucleotide sequences encoding the protease polypeptides, as well as various products and methods useful for the diagnosis and treatment of various protease-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the PTK's and STK's have been identified and their protein structure predicted.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:82657 USPATFULL

TITLE: Novel proteases

INVENTOR(S):
Plowman, Gregory D., San Carlos, CA, UNITED STATES
Whyte, David, Belmont, CA, UNITED STATES
Sudarsanam, Sucha, Greenbrae, CA, UNITED STATES
Manning, Gerard, Menlo Park, CA, UNITED STATES
Caenepeel, Sean R., Oakland, CA, UNITED STATES
Payne, Vilia A., Chesterfield, MO, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2004063107 A1 20040401
APPLICATION INFO.: US 2003-275107 A1 20030320 (10)
WO 2001-US14431 20010504

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW,
WASHINGTON, DC, 20007

NUMBER OF CLAIMS: 28

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 32 Drawing Page(s)

LINE COUNT: 11804

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 7 OF 19 USPATFULL on STN

TI Drug screening systems and assays

AB A method of stimulating non-homologous end-joining (NHEJ) of DNA the method comprising performing NHEJ of DNA in the presence of inositol hexakisphosphate (IP₆) or other stimulatory inositol phosphate. An assay of a protein kinase wherein the assay comprises inositol hexakisphosphate (IP₆) or other stimulatory inositol phosphate. The invention also provides screening assays for compounds which may modulate NHEJ and which may be therapeutically useful; and screening assays for compounds which may modulate DNA-PK and related protein kinases and which may be therapeutically useful. Methods of modulating NHEJ and protein kinases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:38591 USPATFULL

TITLE: Drug screening systems and assays

INVENTOR(S): West, Steve Craig, South Mimms Hertfordshire, UNITED KINGDOM
Bartlett-Jones, Michael, London, UNITED KINGDOM
Akemi Hanakahi, Leslyn Ann, Baltimore, MD, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2004029130 A1 20040212
APPLICATION INFO.: US 2003-296014 A1 20030612 (10)
WO 2001-GB2180 20010518

NUMBER DATE

PRIORITY INFORMATION: GB 2000-12179 20000520

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA,
02110

NUMBER OF CLAIMS: 56

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 18 Drawing Page(s)

LINE COUNT: 2260

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 19 USPATFULL on STN

TI Methods for detecting dna damage and screening for cancer therapeutics
AB A method for detecting DNA damage in a tissue sample involves contacting an immobilized biological sample with a labeled ligand which binds to human 53Bp1, and examining the immobilized sample for the presence of a label generated-detectable signal concentrated in foci in said sample. The presence of concentrated foci is indicative of DNA damage and the presence of diffuse signal is indicative of a normal sample. Diagnostic reagents contain a ligand that binds to human 53Bp1 associated with a detectable label. Diagnostic kits for detecting DNA damage in a biological sample contain such diagnostic reagents and signal detection components. Compositions that inhibit or antagonize the biological activity of 53Bp1 are identified by suitable assays, and are employed in methods of retarding the growth of a cancer cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:31097 USPATFULL

TITLE: Methods for detecting dna damage and screening for cancer therapeutics

INVENTOR(S): Halazonetis, Thanos, Wynnewood, PA, UNITED STATES
Schultz, Linda B., Suwanee, GA, UNITED STATES

| | NUMBER | KIND | DATE |
|---------------------|-----------------|------|---------------|
| PATENT INFORMATION: | US 2004023235 | A1 | 20040205 |
| APPLICATION INFO.: | US 2003-276312 | A1 | 20030117 (10) |
| | WO 2001-US17471 | | 20010530 |

| | NUMBER | DATE |
|-----------------------|--|----------|
| PRIORITY INFORMATION: | US 2000-60208716 | 20000601 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | HOWSON AND HOWSON, ONE SPRING HOUSE CORPORATION CENTER,
BOX 457, 321 NORRISTOWN ROAD, SPRING HOUSE, PA, 19477 | |
| NUMBER OF CLAIMS: | 31 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 2 Drawing Page(s) | |
| LINE COUNT: | 2295 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 19 USPATFULL on STN

TI Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents

AB Systems and methods for modeling the interactions of the several genes, proteins and other components of a cell, employing mathematical techniques to represent the interrelationships between the cell components and the manipulation of the dynamics of the cell to determine which components of a cell may be targets for interaction with therapeutic agents. A first such method is based on a cell simulation approach in which a cellular biochemical network intrinsic to a phenotype of the cell is simulated by specifying its components and their interrelationships. The various interrelationships are represented with one or more mathematical equations which are solved to simulate a first state of the cell. The simulated network is then perturbed by deleting one or more components, changing the concentration of one or more components, or modifying one or more mathematical equations representing the interrelationships between one or more of the components. The equations representing the perturbed network are solved to simulate a second state of the cell which is compared to the first state to identify the effect of the perturbation on the state of the network, thereby identifying one or more components as targets. A second

method for identifying components of a cell as targets for interaction with therapeutic agents is based upon an analytical approach, in which a stable phenotype of a cell is specified and correlated to the state of the cell and the role of that cellular state to its operation. A cellular biochemical network believed to be intrinsic to that phenotype is then specified by identifying its components and their interrelationships and representing those interrelationships in one or more mathematical equations. The network is then perturbed and the equations representing the perturbed network are solved to determine whether the perturbation is likely to cause the transition of the cell from one phenotype to another, thereby identifying one or more components as targets.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:306353 USPATFULL

TITLE: Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents

INVENTOR(S): Hill, Colin, Ithaca, NY, UNITED STATES
Khalil, Iya, Ithaca, NY, UNITED STATES

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2003215786 | A1 | 20031120 |
| APPLICATION INFO.: | US 2002-287173 | A1 | 20021104 (10) |

| | NUMBER | DATE |
|-----------------------|-----------------|---------------|
| PRIORITY INFORMATION: | US 2001-335999P | 20011102 (60) |
| | US 2002-406764P | 20020829 (60) |

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: KRAMER LEVIN NAFTALIS & FRANKEL LLP, INTELLECTUAL PROPERTY DEPARTMENT, 919 THIRD AVENUE, NEW YORK, NY, 10022

NUMBER OF CLAIMS: 65

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 62 Drawing Page(s)

LINE COUNT: 3785

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 19 USPATFULL on STN

TI Novel human protein kinases and protein kinase-like enzymes

AB The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the PTK's and STK's have been identified and their protein structure predicted.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:300763 USPATFULL

TITLE: Novel human protein kinases and protein kinase-like enzymes

INVENTOR(S): Plowman, Gregory D, San Carlos, CA, UNITED STATES
Whyte, David, Belmont, CA, UNITED STATES
Manning, Gerard, Menlo Park, CA, UNITED STATES
Sudarsanam, Sucha, Greenbrae, CA, UNITED STATES
Martinez, Ricardo, Foster City, CA, UNITED STATES

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2003211989 | A1 | 20031113 |
| APPLICATION INFO.: | US 2003-220955 | A1 | 20030226 (10) |

WO 2001-US6838 20010302
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW,
WASHINGTON, DC, 20007
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 7135
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 11 OF 19 USPATFULL on STN
TI Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
AB Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD2-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia/BRCA pathway.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:267307 USPATFULL
TITLE: Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
INVENTOR(S): D'Andrea, Alan D., Winchester, MA, UNITED STATES
Taniguchi, Toshiyasu, Boston, MA, UNITED STATES
Timmers, Cynthia, Columbus, OH, UNITED STATES
Grompe, Markus, Portland, OR, UNITED STATES
Fox, Edward A., Boston, MA, UNITED STATES
PATENT ASSIGNEE(S): Dana Farber Cancer Institute (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---|------|---------------|
| PATENT INFORMATION: | US 2003188326 | A1 | 20031002 |
| APPLICATION INFO.: | US 2002-165099 | A1 | 20020606 (10) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 2001-998027, filed on 2 Nov 2001, PENDING | | |

| | NUMBER | DATE |
|-----------------------|---|---------------|
| PRIORITY INFORMATION: | US 2000-245756P | 20001103 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199 | |
| NUMBER OF CLAIMS: | 41 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 38 Drawing Page(s) | |
| LINE COUNT: | 4045 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 12 OF 19 USPATFULL on STN
TI LGALS as modifiers of the CHK pathway and methods of use
AB Human LGALS genes are identified as modulators of the CHK pathway, and thus are therapeutic targets for disorders associated with defective CHK

function. Methods for identifying modulators of CHK, comprising screening for agents that modulate the activity of LGALS are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:237808 USPATFULL

TITLE: LGALS as modifiers of the CHK pathway and methods of use

INVENTOR(S): Francis-Lang, Helen, San Francisco, CA, UNITED STATES
Nicoll, Monique, Pacifica, CA, UNITED STATES
Heuer, Timothy S., Pacifica, CA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2003165965 A1 20030904

APPLICATION INFO.: US 2003-376133 A1 20030228 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2002-360757P 20020301 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: JAN P. BRUNELLE, EXELIXIS, INC., 170 HARBOR WAY, P.O. BOX 511, SOUTH SAN FRANCISCO, CA, 94083-0511

NUMBER OF CLAIMS: 25

EXEMPLARY CLAIM: 1

LINE COUNT: 2386

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 13 OF 19 USPATFULL on STN

TI Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer

AB The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers. A variety of novel markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:237674 USPATFULL

TITLE: Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer

INVENTOR(S): Lee, John, Somerville, MA, UNITED STATES
Thompson, Pamela, Stow, MA, UNITED STATES
Lillie, James, Natick, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2003165831 A1 20030904

APPLICATION INFO.: US 2001-814353 A1 20010321 (9)

NUMBER DATE

PRIORITY INFORMATION: US 2000-191031P 20000321 (60)

US 2000-207124P 20000525 (60)

US 2000-211940P 20000615 (60)

US 2000-216820P 20000707 (60)

US 2000-220661P 20000725 (60)

US 2000-257672P 20001221 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109

NUMBER OF CLAIMS: 66

EXEMPLARY CLAIM: 1

LINE COUNT: 4104
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 14 OF 19 USPATFULL on STN
TI Full-length human cDNAs encoding potentially secreted proteins
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:219631 USPATFULL
TITLE: Full-length human cDNAs encoding potentially secreted proteins
INVENTOR(S): Dumas Milne Edwards, Jean-Baptiste, Paris, FRANCE
Bougueret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE

| | NUMBER | KIND | DATE |
|-----------------------|---|------|--------------|
| PATENT INFORMATION: | US 2003152921 | A1 | 20030814 |
| APPLICATION INFO.: | US 2001-876997 | A1 | 20010608 (9) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 2000-731872, filed on 7 Dec 2000, PENDING | | |

| | NUMBER | DATE |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | US 1999-169629P | 19991208 (60) |
| | US 2000-187470P | 20000306 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | Frank C. Eisenschenk, Ph.D., SALIWANCHIK, LLOYD & SALIWANCHIK, 2421 N.W. 41 STREET, SUITE A-1, GAINESVILLE, FL, 32606-6669 | |
| NUMBER OF CLAIMS: | 22 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 5 Drawing Page(s) | |
| LINE COUNT: | 27600 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 15 OF 19 USPATFULL on STN
TI Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
AB Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, mapped on the 3p chromosome, cloned into recombinant vectors, used to prepare recombinant cells and sequenced. The FANCD2 gene sequence provides probes and primers for screening patients in genetic based tests and for diagnosing Fanconi anemia and cancer. It has also been possible to target the FANCD2 gene in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. Vectors are described for use in gene therapy. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the mono-ubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact FA pathway. The FANCD2 has been localized to the nucleus and is associated with BRCA 1 foci.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:135730 USPATFULL

TITLE: Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof

INVENTOR(S): D'Andrea, Alan D., Winchester, MA, UNITED STATES
Taniguchi, Toshiyasu, Boston, MA, UNITED STATES
Timmers, Cynthia, Columbus, OH, UNITED STATES
Grompe, Markus, Portland, OR, UNITED STATES

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 2003093819 | A1 | 20030515 |
| APPLICATION INFO.: | US 2001-998027 | A1 | 20011102 (9) |

| | NUMBER | DATE |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | US 2000-245756P | 20001103 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | BROMBERG & SUNSTEIN LLP, 125 SUMMER STREET, BOSTON, MA, 02110-1618 | |
| NUMBER OF CLAIMS: | 76 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 22 Drawing Page(s) | |
| LINE COUNT: | 4421 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 16 OF 19 USPATFULL on STN

TI Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer

AB The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers. A variety of marker genes are provided, wherein changes in the levels of expression of one or more of the marker genes is correlated with the presence of ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:3444 USPATFULL

TITLE: Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
INVENTOR(S): Kovats, Steven G., Wilmington, MA, UNITED STATES
Sen, Ami, Framingham, MA, UNITED STATES
Morrissey, Michael P., Brighton, MA, UNITED STATES
Lillie, James, Natick, MA, UNITED STATES

PATENT ASSIGNEE(S): Millennium Pharmaceutical, Inc., Cambridge, MA (U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2003003479 | A1 | 20030102 |
| APPLICATION INFO.: | US 2002-126227 | A1 | 20020419 (10) |

| | NUMBER | DATE |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | US 2001-285443P | 20010419 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109 | |
| NUMBER OF CLAIMS: | 52 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 5284 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 17 OF 19 USPATFULL on STN
TI Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AB The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers. A variety of markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:322455 USPATFULL
TITLE: Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
INVENTOR(S): Lillie, James, Natick, MA, UNITED STATES
Mills, Gordon, Houston, TX, UNITED STATES
Lee, John, Somerville, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Boston, MA (U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|---------------|------|---------------|
| PATENT INFORMATION: | US 2002182619 | A1 | 20021205 |
| APPLICATION INFO.: | US 2001-35415 | A1 | 20011108 (10) |

| | NUMBER | DATE |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | US 2000-246839P | 20001108 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109 | |
| NUMBER OF CLAIMS: | 8 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 6649 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 18 OF 19 USPATFULL on STN
TI Materials and methods relating to the degradation of Cdc25A in response to DNA damage
AB Cdc25A has a role in a further signalling pathway for DNA repair which operates in response to DNA damage, in which Chk1 or Chk2 are activated following DNA damage and phosphorylate Cdc25A at one or more serine residues, and more particularly at Ser123 and/or Ser262 and/or Ser292 and/or Ser504. The phosphorylated Cdc25A is then recognized by the F-box protein and is then degraded in a proteasome dependent manner, thereby allowing the cells to undergo cell cycle arrest and repair. Accordingly, by interfering with the phosphorylation and/or degradation of Cdc25A and/or using other strategies to maintain Cdc25A level, this pathway can be used to prevent cells from undergoing repair and thereby increasing the accumulation of DNA damage in the cells, e.g. increasing the fraction of tumor cells which can be killed by DNA damaging therapeutic agents, such as radiation or anti-tumor drugs, or which undergo apoptosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:266266 USPATFULL
TITLE: Materials and methods relating to the degradation of Cdc25A in response to DNA damage
INVENTOR(S): Mailand, Niels, Kobenhavn, DENMARK
Hansen, Jacob Falck, Kobenhavn, DENMARK
Bartek, Jiri, Greve, DENMARK
Lukas, Jiri, Greve, DENMARK
Lukas, Claudia, Greve, DENMARK
Syljuasen, Randi, Kobenhavn, DENMARK
Lundgren, Karsten, Fredensborg, DENMARK

PATENT ASSIGNEE(S) : Zealand Pharmaceuticals A/S (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---|------|--------------|
| PATENT INFORMATION: | US 2002147145 | A1 | 20021010 |
| APPLICATION INFO.: | US 2001-949196 | A1 | 20010907 (9) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. WO 2001-GB1008, filed on 8 Mar 2001, UNKNOWN | | |

| | NUMBER | DATE |
|--|---|----------|
| PRIORITY INFORMATION: | GB 2000-5573 | 20000308 |
| | GB 2001-1021 | 20010115 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | Dike, Bronstein, Roberts & Cushman, Intellectual Property Practice Group, EDWARDS & ANGELL, LLP, P.O. Box 9169, Boston, MA, 02209 | |
| NUMBER OF CLAIMS: | 57 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 10 Drawing Page(s) | |
| LINE COUNT: | 2668 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | |

L13 ANSWER 19 OF 19 USPATFULL on STN

TI Full-length human cDNAs encoding potentially secreted proteins
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:191539 USPATFULL
TITLE: Full-length human cDNAs encoding potentially secreted proteins
INVENTOR(S): Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE
Bougueret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 2002102604 | A1 | 20020801 |
| APPLICATION INFO.: | US 2000-731872 | A1 | 20001207 (9) |

| | NUMBER | DATE |
|--|--|---------------|
| PRIORITY INFORMATION: | US 1999-169629P | 19991208 (60) |
| | US 2000-187470P | 20000306 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | John Lucas, Ph.D., J.D., Genset Corporation, 10665 Srento Valley Road, San Diego, CA, 92121-1609 | |
| NUMBER OF CLAIMS: | 29 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 5 Drawing Page(s) | |
| LINE COUNT: | 28061 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | |

=> d 114 ti abs ibib tot

L14 ANSWER 1 OF 12 USPATFULL on STN

TI Stress-responsive activator of p300 (strap) protein

AB The invention provides a protein which is a stress-responsive activator of the p300 protein, and nucleic acid sequences encoding the protein. The protein performs a key role in facilitating stress-responsive protein-protein interactions within the p300 co-activator complex. The STRAP protein facilitates the interaction of other proteins in the p300 complex, and is thus a target for assays for modulators of the complex.

ACCESSION NUMBER: 2004:328237 USPATFULL

TITLE: Stress-responsive activator of p300 (strap) protein

INVENTOR(S): La Thangue, Nicholas Barnie, Strathclyde, UNITED KINGDOM

Demonacos, Constantinos, Strathclyde, UNITED KINGDOM
Krstic-Demonacos, Marija, Strathclyde, UNITED KINGDOM

NUMBER KIND DATE

PATENT INFORMATION: US 2004260062 A1 20041223

APPLICATION INFO.: US 2004-471573 A1 20040816 (10)
WO 2002-GB1349 20020319

NUMBER DATE

PRIORITY INFORMATION: GB 2001-6782 20010319

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: NIXON & VANDERHYE, PC, 1100 N GLEBE ROAD, 8TH FLOOR,
ARLINGTON, VA, 22201-4714

NUMBER OF CLAIMS: 24

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 17 Drawing Page(s)

LINE COUNT: 2276

L14 ANSWER 2 OF 12 USPATFULL on STN

TI p53-dependent apoptosis-inducing protein and method of screening for apoptosis regulator

AB p53-dependent Damage-Inducible Nuclear Protein 1 (p53DINP1 protein) is a p53-induced nuclear protein that induces p53-dependent apoptosis by regulating p53 function through Ser 46 phosphorylation. A DNA encoding p53DINP1 can be applied as anticancer agents for destroying neoplasms such as tumors, and as therapeutic or preventive agents for diseases associated with p53-mediated apoptosis abnormalities. It is also possible to apply the above protein and DNA in methods of screening for candidate compounds for regulating p53-mediated apoptosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:320942 USPATFULL

TITLE: p53-dependent apoptosis-inducing protein and method of screening for apoptosis regulator

INVENTOR(S): Nakamura, Yusuke, Kanagawa, JAPAN
Arakawa, Hirofumi, Tokyo, JAPAN

NUMBER KIND DATE

PATENT INFORMATION: US 2004253595 A1 20041216

APPLICATION INFO.: US 2004-484157 A1 20040726 (10)
WO 2002-JP7305 20020718

NUMBER DATE

PRIORITY INFORMATION: JP 2001-220349 20010719

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Kevin Bastian, Townsend and Townsend and Crew, Two
Embarcadero Center, Eighth Floor, San Francisco, CA,
94111-3834
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1897
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 3 OF 12 USPATFULL on STN
TI Modulators of telomere stability
AB The present invention embodies methods of modulating telomere repeat-binding factor-2 (TRF2) or cell cycle checkpoint kinase 2 (Chk2) to enhance the survival of a cell. More particularly, the modulators can be used to treat cardiovascular disease by improving the growth and survival of cardiomyocytes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:307785 USPATFULL
TITLE: Modulators of telomere stability
INVENTOR(S): Schneider, Michael D., Houston, TX, UNITED STATES
Oh, Hidemasa, Houston, TX, UNITED STATES

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2004242461 | A1 | 20041202 |
| APPLICATION INFO.: | US 2004-820583 | A1 | 20040408 (10) |

| | NUMBER | DATE |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | US 2003-461095P | 20030408 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | FULBRIGHT & JAWORSKI, LLP, 1301 MCKINNEY, SUITE 5100,
HOUSTON, TX, 77010-3095 | |
| NUMBER OF CLAIMS: | 30 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 34 Drawing Page(s) | |
| LINE COUNT: | 4939 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 4 OF 12 USPATFULL on STN
TI Novel SMG-1
AB A novel polypeptide and a novel polynucleotide encoding the same are disclosed.

The polypeptide is SMG-1, a protein included in the phosphatidyl inositol kinase related kinase family, and is useful in constructing a screening system for agents of treating and/or preventing a disease caused by a premature translation termination codon generated by a nonsense mutation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:178425 USPATFULL
TITLE: Novel SMG-1
INVENTOR(S): Ohno, Shigeo, Tokyo, JAPAN
PATENT ASSIGNEE(S): Japan Science and Technology Agency, Saitama, JAPAN
(non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2004137592 | A1 | 20040715 |
| APPLICATION INFO.: | US 2003-720460 | A1 | 20031124 (10) |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-JP10234, filed on 22 Nov 2001, UNKNOWN

| | NUMBER | DATE |
|-----------------------|--|----------|
| PRIORITY INFORMATION: | JP 2001-156088 | 20010524 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | HESLIN ROTHENBERG FARLEY & MESITI PC, 5 COLUMBIA CIRCLE, ALBANY, NY, 12203 | |
| NUMBER OF CLAIMS: | 19 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 14 Drawing Page(s) | |
| LINE COUNT: | 3702 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 5 OF 12 USPATFULL on STN

TI Modulation of checkpoint kinase 1 expression
AB Compounds, compositions and methods are provided for modulating the expression of checkpoint kinase 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding checkpoint kinase 1. Methods of using these compounds for modulation of checkpoint kinase 1 expression and for diagnosis and treatment of disease associated with expression of checkpoint kinase 1 are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:127462 USPATFULL
TITLE: Modulation of checkpoint kinase 1 expression
INVENTOR(S): Gaarde, William, Carlsbad, CA, UNITED STATES
Freier, Susan M., San Diego, CA, UNITED STATES
Dobie, Kenneth W., Del Mar, CA, UNITED STATES
Watt, Andrew T., Vista, CA, UNITED STATES
PATENT ASSIGNEE(S): Isis Pharmaceuticals Inc. (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|--|------|---------------|
| PATENT INFORMATION: | US 2004097446 | A1 | 20040520 |
| APPLICATION INFO.: | US 2002-298994 | A1 | 20021116 (10) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | APPLICATION | | |
| LEGAL REPRESENTATIVE: | WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE - 46TH FLOOR, PHILADELPHIA, PA, 19103 | | |
| NUMBER OF CLAIMS: | 24 | | |
| EXEMPLARY CLAIM: | 1 | | |
| LINE COUNT: | 3681 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 6 OF 12 USPATFULL on STN

TI Drug screening systems and assays
AB A method of stimulating non-homologous end-joining (NHEJ) of DNA the method comprising performing NHEJ of DNA in the presence of inositol hexakisphosphate (IP₆) or other stimulatory inositol phosphate. An assay of a protein kinase wherein the assay comprises inositol hexakisphosphate (IP₆) or other stimulatory inositol phosphate. The invention also provides screening assays for compounds which may modulate NHEJ and which may be therapeutically useful; and screening assays for compounds which may modulate DNA-PK and related protein kinases and which may be therapeutically useful. Methods of modulating NHEJ and protein kinases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:38591 USPATFULL
TITLE: Drug screening systems and assays
INVENTOR(S): West, Steve Craig, South Mimms Hertfordshire, UNITED

KINGDOM
Bartlett-Jones, Michael, London, UNITED KINGDOM
Akemi Hanakahi, Leslyn Ann, Baltimore, MD, UNITED STATES

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2004029130 | A1 | 20040212 |
| APPLICATION INFO.: | US 2003-296014 | A1 | 20030612 (10) |
| | WO 2001-GB2180 | | 20010518 |

| | NUMBER | DATE |
|--|--|----------|
| PRIORITY INFORMATION: | GB 2000-12179 | 20000520 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110 | |
| NUMBER OF CLAIMS: | 56 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 18 Drawing Page(s) | |
| LINE COUNT: | 2260 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | |

L14 ANSWER 7 OF 12 USPATFULL on STN

TI Methods for detecting dna damage and screening for cancer therapeutics
AB A method for detecting DNA damage in a tissue sample involves contacting an immobilized biological sample with a labeled ligand which binds to human 53Bp1, and examining the immobilized sample for the presence of a label generated-detectable signal concentrated in foci in said sample. The presence of concentrated foci is indicative of DNA damage and the presence of diffuse signal is indicative of a normal sample. Diagnostic reagents contain a ligand that binds to human 53Bp1 associated with a detectable label. Diagnostic kits for detecting DNA damage in a biological sample contain such diagnostic reagents and signal detection components. Compositions that inhibit or antagonize the biological activity of 53Bp1 are identified by suitable assays, and are employed in methods of retarding the growth of a cancer cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:31097 USPATFULL
TITLE: Methods for detecting dna damage and screening for cancer therapeutics
INVENTOR(S): Halazonetis, Thanos, Wynnewood, PA, UNITED STATES
Schultz, Linda B., Suwanee, GA, UNITED STATES

| | NUMBER | KIND | DATE |
|---------------------|-----------------|------|---------------|
| PATENT INFORMATION: | US 2004023235 | A1 | 20040205 |
| APPLICATION INFO.: | US 2003-276312 | A1 | 20030117 (10) |
| | WO 2001-US17471 | | 20010530 |

| | NUMBER | DATE |
|--|---|----------|
| PRIORITY INFORMATION: | US 2000-60208716 | 20000601 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | HOWSON AND HOWSON, ONE SPRING HOUSE CORPORATION CENTER, BOX 457, 321 NORRISTOWN ROAD, SPRING HOUSE, PA, 19477 | |
| NUMBER OF CLAIMS: | 31 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 2 Drawing Page(s) | |
| LINE COUNT: | 2295 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | |

L14 ANSWER 8 OF 12 USPATFULL on STN

TI Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents

AB Systems and methods for modeling the interactions of the several genes, proteins and other components of a cell, employing mathematical techniques to represent the interrelationships between the cell components and the manipulation of the dynamics of the cell to determine which components of a cell may be targets for interaction with therapeutic agents. A first such method is based on a cell simulation approach in which a cellular biochemical network intrinsic to a phenotype of the cell is simulated by specifying its components and their interrelationships. The various interrelationships are represented with one or more mathematical equations which are solved to simulate a first state of the cell. The simulated network is then perturbed by deleting one or more components, changing the concentration of one or more components, or modifying one or more mathematical equations representing the interrelationships between one or more of the components. The equations representing the perturbed network are solved to simulate a second state of the cell which is compared to the first state to identify the effect of the perturbation on the state of the network, thereby identifying one or more components as targets. A second method for identifying components of a cell as targets for interaction with therapeutic agents is based upon an analytical approach, in which a stable phenotype of a cell is specified and correlated to the state of the cell and the role of that cellular state to its operation. A cellular biochemical network believed to be intrinsic to that phenotype is then specified by identifying its components and their interrelationships and representing those interrelationships in one or more mathematical equations. The network is then perturbed and the equations representing the perturbed network are solved to determine whether the perturbation is likely to cause the transition of the cell from one phenotype to another, thereby identifying one or more components as targets.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:306353 USPATFULL

TITLE: Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents

INVENTOR(S): Hill, Colin, Ithaca, NY, UNITED STATES
Khalil, Iya, Ithaca, NY, UNITED STATES

| NUMBER | KIND | DATE |
|--------|------|------|
|--------|------|------|

PATENT INFORMATION: US 2003215786 A1 20031120

APPLICATION INFO.: US 2002-287173 A1 20021104 (10)

| NUMBER | DATE |
|--------|------|
|--------|------|

PRIORITY INFORMATION: US 2001-335999P 20011102 (60)

US 2002-406764P 20020829 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: KRAMER LEVIN NAFTALIS & FRANKEL LLP, INTELLECTUAL PROPERTY DEPARTMENT, 919 THIRD AVENUE, NEW YORK, NY, 10022

NUMBER OF CLAIMS: 65

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 62 Drawing Page(s).

LINE COUNT: 3785

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 9 OF 12 USPATFULL on STN

TI Novel human protein kinases and protein kinase-like enzymes
AB The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the PTK's and STK's have been identified and their protein structure predicted.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:300763 USPATFULL

TITLE: Novel human protein kinases and protein kinase-like enzymes

INVENTOR(S): Plowman, Gregory D, San Carlos, CA, UNITED STATES
Whyte, David, Belmont, CA, UNITED STATES
Manning, Gerard, Menlo Park, CA, UNITED STATES
Sudarsanam, Sucha, Greenbrae, CA, UNITED STATES
Martinez, Ricardo, Foster City, CA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2003211989 A1 20031113
APPLICATION INFO.: US 2003-220955 A1 20030226 (10)
WO 2001-US6838 20010302

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW,
WASHINGTON, DC, 20007

NUMBER OF CLAIMS: 28

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 16 Drawing Page(s)

LINE COUNT: 7135

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 10 OF 12 USPATFULL on STN

TI Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof

AB Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia/BRCA pathway.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:267307 USPATFULL

TITLE: Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof

INVENTOR(S): D'Andrea, Alan D., Winchester, MA, UNITED STATES
Taniguchi, Toshiyasu, Boston, MA, UNITED STATES
Timmers, Cynthia, Columbus, OH, UNITED STATES
Grompe, Markus, Portland, OR, UNITED STATES
Fox, Edward A., Boston, MA, UNITED STATES

PATENT ASSIGNEE(S): Dana Farber Cancer Institute (U.S. corporation)

NUMBER KIND DATE

----- ----- -----

PATENT INFORMATION: US 2003188326 A1 20031002
 APPLICATION INFO.: US 2002-165099 A1 20020606 (10)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-998027, filed
 on 2 Nov 2001, PENDING

NUMBER DATE

| | | |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | US 2000-245756P | 20001103 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111
HUNTINGTON AVENUE, BOSTON, MA, 02199 | |
| NUMBER OF CLAIMS: | 41 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 38 Drawing Page(s) | |
| LINE COUNT: | 4045 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 11 OF 12 USPATFULL on STN

TI Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
 AB Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, mapped on the 3p chromosome, cloned into recombinant vectors, used to prepare recombinant cells and sequenced. The FANCD2 gene sequence provides probes and primers for screening patients in genetic based tests and for diagnosing Fanconi anemia and cancer. It has also been possible to target the FANCD2 gene in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. Vectors are described for use in gene therapy. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the mono-ubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact FA pathway. The FANCD2 has been localized to the nucleus and is associated with BRCA 1 foci.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:135730 USPATFULL
 TITLE: Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
 INVENTOR(S): D'Andrea, Alan D., Winchester, MA, UNITED STATES
 Taniguchi, Toshiyasu, Boston, MA, UNITED STATES
 Timmers, Cynthia, Columbus, OH, UNITED STATES
 Grompe, Markus, Portland, OR, UNITED STATES

NUMBER KIND DATE

| | | | |
|---------------------|----------------|----|--------------|
| PATENT INFORMATION: | US 2003093819 | A1 | 20030515 |
| APPLICATION INFO.: | US 2001-998027 | A1 | 20011102 (9) |

NUMBER DATE

| | | |
|-----------------------|---|---------------|
| PRIORITY INFORMATION: | US 2000-245756P | 20001103 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | BROMBERG & SUNSTEIN LLP, 125 SUMMER STREET, BOSTON, MA,
02110-1618 | |
| NUMBER OF CLAIMS: | 76 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 22 Drawing Page(s) | |

LINE COUNT: 4421
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 12 OF 12 USPATFULL on STN
TI Materials and methods relating to the degradation of Cdc25A in response to DNA damage
AB Cdc25A has a role in a further signalling pathway for DNA repair which operates in response to DNA damage, in which Chk1 or Chk2 are activated following DNA damage and phosphorylate Cdc25A at one or more serine residues, and more particularly at Ser123 and/or Ser262 and/or Ser292 and/or Ser504. The phosphorylated Cdc25A is then recognized by the F-box protein and is then degraded in a proteasome dependent manner, thereby allowing the cells to undergo cell cycle arrest and repair. Accordingly, by interfering with the phosphorylation and/or degradation of Cdc25A and/or using other strategies to maintain Cdc25A level, this pathway can be used to prevent cells from undergoing repair and thereby increasing the accumulation of DNA damage in the cells, e.g. increasing the fraction of tumor cells which can be killed by DNA damaging therapeutic agents, such as radiation or anti-tumor drugs, or which undergo apoptosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:266266 USPATFULL
TITLE: Materials and methods relating to the degradation of Cdc25A in response to DNA damage
INVENTOR(S): Mailand, Niels, Kobenhavn, DENMARK
Hansen, Jacob Falck, Kobenhavn, DENMARK
Bartek, Jiri, Greve, DENMARK
Lukas, Jiri, Greve, DENMARK
Lukas, Claudia, Greve, DENMARK
Syljuasen, Randi, Kobenhavn, DENMARK
Lundgren, Karsten, Fredensborg, DENMARK
PATENT ASSIGNEE(S): Zealand Pharmaceuticals A/S (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---|------|--------------|
| PATENT INFORMATION: | US 2002147145 | A1 | 20021010 |
| APPLICATION INFO.: | US 2001-949196 | A1 | 20010907 (9) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. WO 2001-GB1008, filed on 8 Mar 2001, UNKNOWN | | |

| | NUMBER | DATE |
|-----------------------|---|----------|
| PRIORITY INFORMATION: | GB 2000-5573 | 20000308 |
| | GB 2001-1021 | 20010115 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | Dike, Bronstein, Roberts & Cushman, Intellectual Property Practice Group, EDWARDS & ANGELL, LLP, P.O. Box 9169, Boston, MA, 02209 | |

NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 2668
CAS INDEXING IS AVAILABLE FOR THIS PATENT.